In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains

Journal of Chemotherapy

Volumn 13, Issue 4, 2001, Pages 363-376

  Jones, R N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Broad spectrum; Carbapenem; Ertapenem; Long acting; MK 0826; Resistance; Synergy

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

EID: 0034902431     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.4.363     Document Type: Article

References (23)

1. Antibiotic resistance: A current perspective
2. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
3. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-0826 (L-749,345)
4. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates
5. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the Etest ESBL screen
6. Bacterial pathogens isolated from patients with blood stream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada)
7. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview
8. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and inter-laboratory dissemination of extended spectrum β-lactamase producing Enterobacteriaceae
9. Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis
10. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens
11. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against Gram-positive and Gram-negative bacteria
12. Extended spectrum β-lactamases: The role of inhibitors in therapy
13. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
14. Extended spectrum b-lactamases in Pseudomonas aeruginosa
15. Activity of MK-0826 versus β-lactamase producers
16. Worldwide proliferation of carbapenem-resistant Gram-negative bacteria
17. Plasma-mediated dissemination of the metallo-β-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens
18. Appearance of IMP-1 metallo-β-lactamase in Europe
19. Carbapenem-hydrolysing IMP-1 β-lactamase in Klebsiella pneumoniae from Singapore
20. Problems with antimicrobial resistance in Gram-positive cocci
21. Meropenem: A microbiological overview